Company

Celldex Therapeutics, Inc.

Headquarters: Hampton, NJ, United States

Employees: 132

CEO: Mr. Anthony S. Marucci M.B.A.

NASDAQ: CLDX -7.98%

Market Cap

$1.59 Billion

USD as of Jan. 1, 2025

Market Cap History

Celldex Therapeutics, Inc. market capitalization over time

Evolution of Celldex Therapeutics, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Celldex Therapeutics, Inc.

Detailed Description

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Top 1-year algo backtest: +327.04%

$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Financials

Last Financial Reports Date Sept. 30, 2024
Revenue TTM $10.0 M
EBITDA $-171,060,992
Gross Profit TTM $-137,060,992
Profit Margin 0.00%
Operating Margin -1633.53%
Quarterly Revenue Growth 110.30%
Financial Reports & Statistics

Stocks & Indices

Celldex Therapeutics, Inc. has the following listings and related stock indices.


Stock: NASDAQ: CLDX wb_incandescent

Stock: FSX: TCE2 wb_incandescent

Details

Headquarters:

Perryville III Building

Suite 220 53 Frontage Road

Hampton, NJ 08827

United States

Phone: 908 200 7500

Fax: 908 454 1911